Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VNRX Stock Forecast 2026-2027
$1.30
Current Price
$15.50M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to VNRX Price Targets
+1,746.2%
To High Target of $24.00
+1,438.5%
To Median Target of $20.00
+207.7%
To Low Target of $4.00
VNRX Price Momentum
-7.1%
1 Week Change
-5.8%
1 Month Change
-90.4%
1 Year Change
-75.0%
Year-to-Date Change
-91.9%
From 52W High of $16.00
+11.1%
From 52W Low of $1.17
📊 TOP ANALYST CALLS
Did VNRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if VolitionRX is one of their latest high-conviction picks.
Latest VNRX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, VNRX has a bullish consensus with a median price target of $20.00 (ranging from $4.00 to $24.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $1.30, the median forecast implies a 1,438.5% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VNRX Analyst Ratings
4
Buy
1
Hold
0
Sell
VNRX Price Target Range
Low
$4.00
Average
$20.00
High
$24.00
Current: $1.30
Latest VNRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VNRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 20, 2026 | D. Boral Capital | Hold | Downgrade | $N/A | |
| Apr 2, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 31, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 26, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 18, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 21, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 9, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 18, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 4, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 3, 2025 | Maxim Group | Hold | Downgrade | $N/A | |
| Nov 26, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 21, 2025 | Freedom Broker | Buy | Maintains | $N/A | |
| Nov 17, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 17, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 30, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 29, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 10, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 15, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jul 17, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jul 9, 2025 | D. Boral Capital | Buy | Maintains | $N/A |
VolitionRx Limited (VNRX) Competitors
The following stocks are similar to VolitionRX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VolitionRx Limited (VNRX) Financial Data
VolitionRx Limited has a market capitalization of $15.50M with a P/E ratio of -0.3x. The company generates $2.47M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +299.8% quarter-over-quarter, while maintaining an operating margin of -543.0% and return on equity of +65.6%.
Valuation Metrics
Market Cap
$15.50M
Enterprise Value
$18.46M
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
6.5x
Growth & Margins
Revenue Growth (YoY)
+299.8%
Gross Margin
N/A
Operating Margin
-543.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+28.6%
Current Ratio
0.3x
Debt/Equity
-0.4x
ROE
+65.6%
ROA
-153.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
VolitionRx Limited (VNRX) Business Model
About VolitionRx Limited
What They Do
Develops blood-based diagnostic tests for diseases.
Business Model
The company leverages its proprietary Nucleosomics platform to create and commercialize diagnostic assays that measure nucleosomes and biomarkers in blood and other fluids. By offering cost-effective and easy-to-use tests, it integrates into routine clinical workflows, facilitating early disease detection and monitoring for healthcare providers.
Additional Information
Founded in 2010 and headquartered in Henderson, Nevada, VolitionRx operates globally with a strong R&D presence in Belgium and additional operations in the US, UK, and Singapore. The company serves both human and veterinary diagnostics markets, focusing on critical diseases such as cancer and conditions linked to NETosis.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
67
CEO
Mr. Cameron Reynolds MBA
Country
United States
IPO Year
2012
Website
volition.comVolitionRx Limited (VNRX) Latest News & Analysis
Latest News
Quick Summary
VolitionRx Limited (VNRX) reported a new clinical study showing its Nu.Q® Cancer Assay provides significant prognostic value for newly diagnosed lung cancer patients, aiding in treatment personalization.
Why It Matters
The new clinical study on VolitionRx's Nu.Q® Cancer Assay enhances its market position in oncology, potentially increasing demand for its products and driving stock value upward.
Source: PRNewsWire
Market Sentiment:
Neutral
VolitionRx Announces Collaboration with Sysmex
27 days ago
Quick Summary
VolitionRx Limited (VNRX) has partnered with Sysmex (TYO: 6869) to enhance the Nu.Q® NETs H3.1 assay on Sysmex's diagnostic platform.
Why It Matters
The collaboration between VolitionRx and Sysmex may enhance assay performance, potentially increasing market adoption and revenue, positively impacting Volition's stock value and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited announced a public offering of 2.96 million shares and warrants for 1.48 million shares at $1.55 each, raising $4.6 million upfront, with potential additional proceeds of $2.3 million.
Why It Matters
VolitionRx's public offering raises $4.6 million, with potential for $2.3 million more. This capital can fund growth initiatives, impacting future stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
1 month ago
Quick Summary
VolitionRx Limited (NYSE: VNRX) has filed a patent for its Nu.Q® technology to aid in triaging and monitoring Ebola virus patients, seeking strategic partners for deployment in outbreak zones.
Why It Matters
VolitionRx's patent for Nu.Q® technology in Ebola triage enhances its market position, potentially boosting revenue and attracting strategic partnerships, which could positively impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx reports 300% Q1 revenue growth, nearing a $5 million milestone in veterinary diagnostics, and is in licensing talks with over a dozen global diagnostic leaders.
Why It Matters
VolitionRx's 300% Q1 revenue growth and advancements toward a $5 million milestone signal strong market demand and potential profitability, attracting investor interest in its growth trajectory.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited (VNRX) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Further details on revenue and future outlook were provided.
Why It Matters
Earnings calls provide insights into a company's financial health and future outlook, influencing stock performance and investor sentiment. VolitionRx's Q1 2026 results could impact its valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About VNRX Stock
What is VolitionRx Limited's (VNRX) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, VolitionRx Limited (VNRX) has a median price target of $20.00. The highest price target is $24.00 and the lowest is $4.00.
Is VNRX stock a good investment in 2027?
According to current analyst ratings, VNRX has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VNRX stock?
Wall Street analysts predict VNRX stock could reach $20.00 in the next 12 months. This represents a 1,438.5% increase from the current price of $1.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is VolitionRx Limited's business model?
The company leverages its proprietary Nucleosomics platform to create and commercialize diagnostic assays that measure nucleosomes and biomarkers in blood and other fluids. By offering cost-effective and easy-to-use tests, it integrates into routine clinical workflows, facilitating early disease detection and monitoring for healthcare providers.
What is the highest forecasted price for VNRX VolitionRx Limited?
The highest price target for VNRX is $24.00 from at , which represents a 1,746.2% increase from the current price of $1.30.
What is the lowest forecasted price for VNRX VolitionRx Limited?
The lowest price target for VNRX is $4.00 from at , which represents a 207.7% increase from the current price of $1.30.
What is the overall VNRX consensus from analysts for VolitionRx Limited?
The overall analyst consensus for VNRX is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are VNRX stock price projections?
Stock price projections, including those for VolitionRx Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 4:07 AM UTC